Vanguard Capital Management
PMVP icon

Vanguard Capital Management’s PMV Pharmaceuticals PMVP Stock Holding History

Vanguard Capital Management’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.7M Buy
2,012,020
+37,114
+2% +$47.6K ﹤0.01% 3318
2026
Q1 		$2.45M Buy
+1,974,906
New +$2.51M ﹤0.01% 3297

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management's PMVP Position: Q2 2026 in Review

Vanguard Capital Management increased its PMV Pharmaceuticals (PMVP) stake by 1.9% in Q2 2026, buying an estimated $47.6K and bringing the position to 2,012,020 shares worth $2.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3318.

Vanguard Capital Management first reported a position in PMVP in Q1 2026 and has held it in 2 quarters since. 62 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

  • Vanguard Capital Management held 2,012,020 shares of PMV Pharmaceuticals worth $2.7M as of Q2 2026.
  • Vanguard Capital Management bought 37,114 PMV Pharmaceuticals shares in Q2 2026, an estimated $47.6K.
  • PMV Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3318 holding.
  • Vanguard Capital Management first reported a position in PMV Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 62 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.